Susan M Goodman1, Indu Menon2, Paul J Christos3, Rie Smethurst4, Vivian P Bykerk5. 1. Department of Medicine, Weill Cornell Medical College, Division of Rheumatology, Hospital for Special Surgery, goodmans@hss.edu. 2. Research Division, Hospital for Special Surgery. 3. Division of Biostatistics and Epidemiology, Weill Cornell Medical College and. 4. Department of Academic Training, Education Division, Hospital for Special Surgery, New York, NY, USA. 5. Department of Medicine, Weill Cornell Medical College, Division of Rheumatology, Hospital for Special Surgery.
Abstract
OBJECTIVE: Tumour necrosis factor α inhibitors (TNFis) are widely used in RA patients who undergo surgery, and optimal perioperative management must balance the risk of infection with the risk of post-operative flare. The purpose of this study is to examine the impact of TNFi exposure on surgical site infections (SSIs) in RA patients undergoing elective orthopaedic surgery by systematic review and meta-analysis. METHODS: A systematic review of the literature and meta-analysis were performed using PUBMED, EMBASE and the Cochrane Central Register of Controlled Trials, through May 2014. Two independent reviewers screened titles and abstracts, and analysed selected papers in detail. Included studies assessed RA patients with or without TNFi exposure prior to orthopaedic surgery, and described post-operative infections. Study quality was assessed using the Oxford Centre for Evidence-based Medicine Levels of Evidence. Meta-analyses of the individual study odds ratios (ORs) were conducted, and each pooled OR was calculated using a random effects model. RESULTS: Eight observational studies and three case control studies met inclusion criteria; risk of bias was low in eight studies and moderate in three. Publication bias was not apparent. These studies represent 3681 patients with recent exposure to TNFis (TNFi+) and 4310 with no recent exposure to TNFis (TNFi-) at the time of surgery. The TNFi+ group had higher risk of developing SSI compared with patients in the TNFi- group (random effects model: OR 2.47 (95% CI 1.66, 3.68); P < 0.0001). CONCLUSION: Data from the available literature suggest that there is an increased risk of SSIs in RA patients who use or have recently used TNFis at the time of elective orthopaedic surgery. Prospective studies to confirm these findings and establish the optimal withhold and restart time of TNFis, in the context of other risk factors for infection in RA patients such as higher disease activity, corticosteroid use, smoking and diabetes, are needed.
OBJECTIVE:Tumour necrosis factor α inhibitors (TNFis) are widely used in RApatients who undergo surgery, and optimal perioperative management must balance the risk of infection with the risk of post-operative flare. The purpose of this study is to examine the impact of TNFi exposure on surgical site infections (SSIs) in RApatients undergoing elective orthopaedic surgery by systematic review and meta-analysis. METHODS: A systematic review of the literature and meta-analysis were performed using PUBMED, EMBASE and the Cochrane Central Register of Controlled Trials, through May 2014. Two independent reviewers screened titles and abstracts, and analysed selected papers in detail. Included studies assessed RApatients with or without TNFi exposure prior to orthopaedic surgery, and described post-operative infections. Study quality was assessed using the Oxford Centre for Evidence-based Medicine Levels of Evidence. Meta-analyses of the individual study odds ratios (ORs) were conducted, and each pooled OR was calculated using a random effects model. RESULTS: Eight observational studies and three case control studies met inclusion criteria; risk of bias was low in eight studies and moderate in three. Publication bias was not apparent. These studies represent 3681 patients with recent exposure to TNFis (TNFi+) and 4310 with no recent exposure to TNFis (TNFi-) at the time of surgery. The TNFi+ group had higher risk of developing SSI compared with patients in the TNFi- group (random effects model: OR 2.47 (95% CI 1.66, 3.68); P < 0.0001). CONCLUSION: Data from the available literature suggest that there is an increased risk of SSIs in RApatients who use or have recently used TNFis at the time of elective orthopaedic surgery. Prospective studies to confirm these findings and establish the optimal withhold and restart time of TNFis, in the context of other risk factors for infection in RApatients such as higher disease activity, corticosteroid use, smoking and diabetes, are needed.
Authors: Tina Ding; Jo Ledingham; Raashid Luqmani; Sarah Westlake; Kimme Hyrich; Mark Lunt; Patrick Kiely; Marwan Bukhari; Rikki Abernethy; Ailsa Bosworth; Andrew Ostor; Kate Gadsby; Frank McKenna; Diana Finney; Josh Dixey; Chris Deighton Journal: Rheumatology (Oxford) Date: 2010-09-12 Impact factor: 7.580
Authors: Geertje M Bartelds; Charlotte L M Krieckaert; Michael T Nurmohamed; Pauline A van Schouwenburg; Willem F Lems; Jos W R Twisk; Ben A C Dijkmans; Lucien Aarden; Gerrit Jan Wolbink Journal: JAMA Date: 2011-04-13 Impact factor: 56.272
Authors: E F Berbari; A D Hanssen; M C Duffy; J M Steckelberg; D M Ilstrup; W S Harmsen; D R Osmon Journal: Clin Infect Dis Date: 1998-11 Impact factor: 9.079
Authors: Catrina B Scherrer; Anne F Mannion; Diego Kyburz; Markus Vogt; Inès A Kramers-de Quervain Journal: Arthritis Care Res (Hoboken) Date: 2013-12 Impact factor: 4.794
Authors: Tim Bongartz; Christine S Halligan; Douglas R Osmon; Megan S Reinalda; William R Bamlet; Cynthia S Crowson; Arlen D Hanssen; Eric L Matteson Journal: Arthritis Rheum Date: 2008-12-15
Authors: A Ruyssen-Witrand; L Gossec; C Salliot; M Luc; M Duclos; S Guignard; M Dougados Journal: Clin Exp Rheumatol Date: 2007 May-Jun Impact factor: 4.473
Authors: Susan M Goodman; Allina A Nocon; Nicolas A Selemon; Bo Shopsin; Yi Fulmer; Mary E Decker; Sarah E Grond; Laura T Donlin; Mark P Figgie; Thomas P Sculco; Linda A Russell; Michael E Henry; Anne R Bass; Andy O Miller; Peter K Sculco Journal: J Arthroplasty Date: 2019-01-17 Impact factor: 4.757
Authors: Susan M Goodman; Serene Z Mirza; Edward F DiCarlo; Diyu Pearce-Fisher; Meng Zhang; Bella Mehta; Laura T Donlin; Vivian P Bykerk; Mark P Figgie; Dana E Orange Journal: Arthritis Care Res (Hoboken) Date: 2020-05-14 Impact factor: 4.794
Authors: Michael D George; Joshua F Baker; Jesse Yenchih Hsu; Qufei Wu; Fenglong Xie; Lang Chen; Huifeng Yun; Jeffrey R Curtis Journal: Arthritis Care Res (Hoboken) Date: 2017-11-02 Impact factor: 4.794
Authors: Namrata Singh; Rajeshwari Nair; Michihiko Goto; Martha L Carvour; Ryan Carnahan; Elizabeth H Field; Petar Lenert; Mary Vaughan-Sarrazin; Marin L Schweizer; Eli N Perencevich Journal: Open Forum Infect Dis Date: 2019-10-19 Impact factor: 3.835
Authors: Martin H Gregory; Andrew McKinnon; Dustin Stwalley; Kirk J Hippensteel; Edward V Loftus; Matthew A Ciorba; Margaret A Olsen; Parakkal Deepak Journal: J Crohns Colitis Date: 2019-02-01 Impact factor: 9.071